Derrick Gibbings: Single Dose of Experimental Compound Blocks Disease for Six Months

Researchers at the University of Ottawa have highlighted a promising approach in gene therapy that could allow a single dose to block the expression of a disease-causing gene for up to six months. This finding centers on the use of small extracellular vesicles (sEVs) as natural delivery systems for therapeutic molecules like small interfering RNA (siRNA), which can silence specific genes involved in disease.

According to Dr. Derrick Gibbings, professor in the Department of Cellular and Molecular Medicine at the University of Ottawa’s Faculty of Medicine and senior author of the study, siRNAs are powerful therapeutics capable of achieving prolonged gene silencing when delivered effectively. In a university press release dated April 16, 2026, Dr. Gibbings stated: “siRNAs are incredible therapeutics… A single dose… can block expression of a disease-causing gene for 6 months.”

The research, published in the journal Cell Biomaterials, involved an international team including scientists from Brazil and the United States. The team investigated how sEVs—tiny, bubble-like particles released by cells—naturally transport RNA and other molecules between cells. Their work revealed that not all sEVs function identically; the cell type that produces these vesicles determines where they travel in the body, enabling certain sEVs to target specific tissues such as the brain or kidneys.

This biological precision offers a potential solution to one of the major challenges in gene therapy: delivering treatments accurately to the intended cells without affecting others. By leveraging the natural targeting ability of sEVs, researchers aim to improve the safety and effectiveness of RNA-based therapies, particularly for diseases affecting hard-to-reach organs.

Despite the promise, significant hurdles remain before such treatments can be widely used. As noted by Dr. Gibbings and reported by the University of Ottawa, two primary challenges persist: producing sEVs at the large scale needed for clinical applications and improving how long siRNA remains active in the body after delivery. Overcoming these obstacles will require further research and technological advances in biomanufacturing and molecular stabilization.

Dr. Gibbings’ laboratory focuses on RNA biology and extracellular vesicles, with particular attention to autophagy and exosome function. His team previously identified a mechanism for transporting RNA and microRNA complexes into exosomes, a discovery that has already been adapted into a diagnostic tool used in clinical settings. This ongoing work reflects broader efforts to harness natural cellular processes for medical innovation, especially in treating conditions like cancer, neuromuscular disorders, and viral infections.

The University of Ottawa press release emphasizes that while the scientific foundation is strong, the research is still in progress. Clinical applications are not imminent, and the six-month duration of gene silencing has not yet been validated in human trials. The findings represent a step forward in refining delivery mechanisms for gene-silencing therapies, but additional study is needed to confirm safety, efficacy, and scalability in real-world medical use.